Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

The AP-1 transcriptional complex: Local switch or remote command?

Bejjani F, Evanno E, Zibara K, Piechaczyk M, Jariel-Encontre I.

Biochim Biophys Acta Rev Cancer. 2019 Apr 26;1872(1):11-23. doi: 10.1016/j.bbcan.2019.04.003. [Epub ahead of print] Review.

PMID:
31034924
2.

Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.

Naranjo-Gomez M, Lambour J, Piechaczyk M, Pelegrin M.

JCI Insight. 2018 May 3;3(9). pii: 97339. doi: 10.1172/jci.insight.97339.

3.

Targeting the SUMO Pathway Primes All-trans Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias.

Baik H, Boulanger M, Hosseini M, Kowalczyk J, Zaghdoudi S, Salem T, Sarry JE, Hicheri Y, Cartron G, Piechaczyk M, Bossis G.

Cancer Res. 2018 May 15;78(10):2601-2613. doi: 10.1158/0008-5472.CAN-17-3361. Epub 2018 Feb 27.

4.

Production and Purification of Recombinant SUMOylated Proteins Using Engineered Bacteria.

Brockly F, Piechaczyk M, Bossis G.

Methods Mol Biol. 2016;1475:55-65. doi: 10.1007/978-1-4939-6358-4_4.

PMID:
27631797
5.

Detection of Protein-Protein Interactions and Posttranslational Modifications Using the Proximity Ligation Assay: Application to the Study of the SUMO Pathway.

Ristic M, Brockly F, Piechaczyk M, Bossis G.

Methods Mol Biol. 2016;1449:279-90. doi: 10.1007/978-1-4939-3756-1_17.

PMID:
27613043
6.

Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.

Lambour J, Naranjo-Gomez M, Piechaczyk M, Pelegrin M.

Emerg Microbes Infect. 2016 Aug 17;5(8):e92. doi: 10.1038/emi.2016.97. Review.

7.

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Pelegrin M, Naranjo-Gomez M, Piechaczyk M.

Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005. Review.

PMID:
26433697
8.

c-Fos Protects Neurons Through a Noncanonical Mechanism Involving HDAC3 Interaction: Identification of a 21-Amino Acid Fragment with Neuroprotective Activity.

Rawat V, Goux W, Piechaczyk M, D'Mello SR.

Mol Neurobiol. 2016 Mar;53(2):1165-80. doi: 10.1007/s12035-014-9058-1. Epub 2015 Jan 16.

9.

Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.

Moquet-Torcy G, Tolza C, Piechaczyk M, Jariel-Encontre I.

Nucleic Acids Res. 2014;42(17):11011-24. doi: 10.1093/nar/gku814. Epub 2014 Sep 8.

10.

The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.

Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, Pelegrin M, Kaoma T, Vallar L, Récher C, Manenti S, Piechaczyk M.

Cell Rep. 2014 Jun 26;7(6):1815-23. doi: 10.1016/j.celrep.2014.05.016. Epub 2014 Jun 5.

11.

Chromatin loop organization of the junb locus in mouse dendritic cells.

Salem T, Gomard T, Court F, Moquet-Torcy G, Brockly F, Forné T, Piechaczyk M.

Nucleic Acids Res. 2013 Oct;41(19):8908-25. doi: 10.1093/nar/gkt669. Epub 2013 Aug 5.

12.

[Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?].

Pelegrin M, Gros L, Piechaczyk M.

Med Sci (Paris). 2013 May;29(5):457-60. doi: 10.1051/medsci/2013295005. Epub 2013 May 28. French. No abstract available.

13.

SUMOylation of the inducible (c-Fos:c-Jun)/AP-1 transcription complex occurs on target promoters to limit transcriptional activation.

Tempé D, Vives E, Brockly F, Brooks H, De Rossi S, Piechaczyk M, Bossis G.

Oncogene. 2014 Feb 13;33(7):921-7. doi: 10.1038/onc.2013.4. Epub 2013 Feb 11.

PMID:
23396363
14.

Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies.

Nasser R, Pelegrin M, Plays M, Gros L, Piechaczyk M.

Blood. 2013 Feb 14;121(7):1102-11. doi: 10.1182/blood-2012-06-432153. Epub 2012 Dec 20.

15.

GSK3-SCF(FBXW7) targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase.

Pérez-Benavente B, García JL, Rodríguez MS, Pineda-Lucena A, Piechaczyk M, Font de Mora J, Farràs R.

Oncogene. 2013 Apr 25;32(17):2189-99. doi: 10.1038/onc.2012.235. Epub 2012 Jun 18.

PMID:
22710716
16.

The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D.

Oncogene. 2012 Nov 22;31(47):4889-97. doi: 10.1038/onc.2011.659. Epub 2012 Jan 30.

17.

Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL.

Sayan AE, Stanford R, Vickery R, Grigorenko E, Diesch J, Kulbicki K, Edwards R, Pal R, Greaves P, Jariel-Encontre I, Piechaczyk M, Kriajevska M, Mellon JK, Dhillon AS, Tulchinsky E.

Oncogene. 2012 Mar 22;31(12):1493-503. doi: 10.1038/onc.2011.336. Epub 2011 Aug 8.

PMID:
21822309
18.

Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, Gros L.

J Virol. 2010 Oct;84(19):10169-81. doi: 10.1128/JVI.00568-10. Epub 2010 Jul 7.

19.

A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.

Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, Jacquet C, Hernandez J, Piechaczyk M, Pelegrin M.

PLoS Pathog. 2010 Jun 10;6(6):e1000948. doi: 10.1371/journal.ppat.1000948.

20.

Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein.

Talotta F, Mega T, Bossis G, Casalino L, Basbous J, Jariel-Encontre I, Piechaczyk M, Verde P.

Oncogene. 2010 Aug 19;29(33):4732-40. doi: 10.1038/onc.2010.211. Epub 2010 Jun 14.

PMID:
20543861
21.

An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells.

Gomard T, Michaud HA, Tempé D, Thiolon K, Pelegrin M, Piechaczyk M.

PLoS One. 2010 Mar 8;5(3):e9585. doi: 10.1371/journal.pone.0009585.

22.

Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution.

Malnou CE, Brockly F, Favard C, Moquet-Torcy G, Piechaczyk M, Jariel-Encontre I.

J Biol Chem. 2010 Feb 26;285(9):6552-62. doi: 10.1074/jbc.M109.032680. Epub 2010 Jan 6.

23.

Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity.

Brunet Simioni M, De Thonel A, Hammann A, Joly AL, Bossis G, Fourmaux E, Bouchot A, Landry J, Piechaczyk M, Garrido C.

Oncogene. 2009 Sep 17;28(37):3332-44. doi: 10.1038/onc.2009.188. Epub 2009 Jul 13.

PMID:
19597476
24.

SUMO under stress.

Tempé D, Piechaczyk M, Bossis G.

Biochem Soc Trans. 2008 Oct;36(Pt 5):874-8. doi: 10.1042/BST0360874. Review.

PMID:
18793154
25.

Regulation and function of JunB in cell proliferation.

Piechaczyk M, Farràs R.

Biochem Soc Trans. 2008 Oct;36(Pt 5):864-7. doi: 10.1042/BST0360864. Review.

PMID:
18793152
26.

Fos family protein degradation by the proteasome.

Gomard T, Jariel-Encontre I, Basbous J, Bossis G, Moquet-Torcy G, Piechaczyk M.

Biochem Soc Trans. 2008 Oct;36(Pt 5):858-63. doi: 10.1042/BST0360858. Erratum in: Biochem Soc Trans. 2013 Dec;41(6):1773. Mocquet-Torcy, Gabriel [corrected to Moquet-Torcy, Gabriel].

PMID:
18793151
27.

Ubiquitin-independent degradation of proteins by the proteasome.

Jariel-Encontre I, Bossis G, Piechaczyk M.

Biochim Biophys Acta. 2008 Dec;1786(2):153-77. doi: 10.1016/j.bbcan.2008.05.004. Epub 2008 Jun 17. Review.

PMID:
18558098
28.

SUMOylation regulates the transcriptional activity of JunB in T lymphocytes.

Garaude J, Farrás R, Bossis G, Charni S, Piechaczyk M, Hipskind RA, Villalba M.

J Immunol. 2008 May 1;180(9):5983-90.

29.

JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.

Farràs R, Baldin V, Gallach S, Acquaviva C, Bossis G, Jariel-Encontre I, Piechaczyk M.

Mol Cell Biol. 2008 Jun;28(12):4173-87. doi: 10.1128/MCB.01620-07. Epub 2008 Apr 7.

30.

A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking.

Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, Jariel-Encontre I, Piechaczyk M, Bertrand E, Tazi J, Coux O.

Mol Biol Cell. 2008 Apr;19(4):1706-16. doi: 10.1091/mbc.E07-07-0637. Epub 2008 Feb 6.

31.

Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.

Gros L, Pelegrin M, Michaud HA, Bianco S, Hernandez J, Jacquet C, Piechaczyk M.

J Virol. 2008 Feb;82(3):1339-49. Epub 2007 Nov 21.

32.

Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?

Basbous J, Jariel-Encontre I, Gomard T, Bossis G, Piechaczyk M.

Biochimie. 2008 Feb;90(2):296-305. Epub 2007 Jul 31. Review.

PMID:
17825471
33.

Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic.

Malnou CE, Salem T, Brockly F, Wodrich H, Piechaczyk M, Jariel-Encontre I.

J Biol Chem. 2007 Oct 19;282(42):31046-59. Epub 2007 Aug 6.

34.

Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer.

Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M.

Mol Cell Biol. 2007 Jun;27(11):3936-50. Epub 2007 Mar 19.

35.
36.
37.

Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.

Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind R, Rodriguez M, Schmidt D, Muller S, Jariel-Encontre I, Piechaczyk M.

Mol Cell Biol. 2005 Aug;25(16):6964-79.

38.

Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Gros L, Dreja H, Fiser AL, Plays M, Pelegrin M, Piechaczyk M.

J Virol. 2005 May;79(10):6272-80.

39.

Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?

Farràs R, Bossis G, Andermarcher E, Jariel-Encontre I, Piechaczyk M.

Crit Rev Oncol Hematol. 2005 Apr;54(1):31-51. Review.

PMID:
15780906
40.

[Proteasomal degradation: from addressing of substrates to therapeutical perspectives].

Andermarcher E, Bossis G, Farras R, Jariel-Encontre I, Piechaczyk M.

Med Sci (Paris). 2005 Feb;21(2):141-9. Review. French.

41.

Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells.

Bachrach E, Dreja H, Lin YL, Mettling C, Pinet V, Corbeau P, Piechaczyk M.

Virology. 2005 Feb 5;332(1):418-29.

42.

Monoclonal antibody-based genetic immunotherapy.

Pelegrin M, Gros L, Dreja H, Piechaczyk M.

Curr Gene Ther. 2004 Sep;4(3):347-56. Review.

PMID:
15384948
43.

SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1.

Salinas S, Briançon-Marjollet A, Bossis G, Lopez MA, Piechaczyk M, Jariel-Encontre I, Debant A, Hipskind RA.

J Cell Biol. 2004 Jun 21;165(6):767-73.

44.

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation.

Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegrin M.

Genet Vaccines Ther. 2004 Mar 23;2(1):2.

45.

c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo.

Bossis G, Ferrara P, Acquaviva C, Jariel-Encontre I, Piechaczyk M.

Mol Cell Biol. 2003 Oct;23(20):7425-36.

46.

Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor.

Dreja H, Gros L, Villard S, Bachrach E, Oates A, Granier C, Chardes T, Mani JC, Piechaczyk M, Pelegrin M.

J Virol. 2003 Oct;77(20):10984-93.

47.

The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity.

Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, Mesnard JM.

J Biol Chem. 2003 Oct 31;278(44):43620-7. Epub 2003 Aug 22.

48.

The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression.

Ferrara P, Andermarcher E, Bossis G, Acquaviva C, Brockly F, Jariel-Encontre I, Piechaczyk M.

Oncogene. 2003 Mar 13;22(10):1461-74.

PMID:
12629509
49.

In vivo infection of mice by replication-competent MLV-based retroviral vectors.

Bachrach E, Duch M, Pelegrin M, Dreja H, Pedersen FS, Piechaczyk M.

Methods Mol Med. 2003;76:343-52. No abstract available.

PMID:
12526173
50.

Multiple degradation pathways for Fos family proteins.

Acquaviva C, Bossis G, Ferrara P, Brockly F, Jariel-Encontre I, Piechaczyk M.

Ann N Y Acad Sci. 2002 Nov;973:426-34. Review.

PMID:
12485905

Supplemental Content

Loading ...
Support Center